Background The aim of this study was to analyze the total outpatient utilization of antibacterials for systemic use (ATC class J01) and the outpatient utilization of antibiotics on the reimbursable medication list of the Health Insurance Fund, in the Republic of Srpska, in 2007 and 2008. Methods In the retrospective study outpatient utilization of prescription-only antibacterials for systemic use dispensed in pharmacies was analyzed. Anatomical therapeutic chemical/defined daily dose methodology was used to monitor drug utilization.
Antibiotics are important and widely used medicines. 1, 2 In human medicine, about 80-90% of antibiotics are used in outpatient and the rest in hospitalized patients. 3 Overuse and/or misuse of antibiotics have significant consequences, such as increased costs, therapeutic failure, drug toxicity, drug interactions, and bacterial resistance. In developing countries, on average, 35 per cent of the total health budget is spent on antibiotics. 4 Antimicrobial drug resistance is a rapidly increasing global problem. 5, 6 Prevalence of resistance is positively correlated with prescribed outpatient antibiotic use at national level. Although antibiotics are prescription-only medicines, actual consumption may also include self-medication. 2, 6, 7 Cultural factors to play important role in the consumption of antibiotics. 8, 9 Thus, information on the trends, patterns, and determinants of antibiotic consumption is essential to determine areas where improvement is needed.
Until recently, information on outpatient antibiotic consumption in various countries was limited. In 2001, Cars et al. 3 published comparable outpatient antibiotic use in fifteen European countries. A compulsory reporting of health institutions to Drug Regulatory Agency of the Republic of Srpska (DRA) on drugs utilization started in year 2006, when a related by-law came into action. 10 Up to 2006, there were no comprehensive data available for analysis of total outpatient antibiotic utilization in the Republic of Srpska. Therefore, only the data on utilization of drugs on the reimbursable medication list of the Republic of Srpska Health Insurance Fund (HIF) were available and reliable source for analysis on drugs utilization and prescribing patterns. 11, 12 The aim of this study was to analyze the total outpatient utilization of antibiotics classified in ATC group J01 and the outpatient utilization of antibiotics on the reimbursable medication list of the Health Insurance Fund, in 2007 and 2008.
Methods
The outpatient utilization of all prescription-only drugs and the outpatient utilization of drugs on the reimbursable medication list of the Health Insurance Fund was analyzed (Table 2) , using anatomical therapeutic chemical/defined daily dose methodology (ATC/DDD methodology). The ATC system classifies the drugs into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutic properties. The drugs were classified into ATC groups by its international non-proprietary name (INN), and the results were expressed as a DDD per thousand inhabitants per day (DDD/ TID). The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults, and its use in DDD/TID is to enable a study of the extent of medicine utilization in a defined area and its changes over certain time period. The DDD/TID is a useful indicator for national and international comparisons, especially when areas to be compared have different number of inhabitants. 13, 14 Hereafter in this article, the acronym DDD should be taken to indicate DDD/TID. Utilization of antibacterials for systemic use (ATC class J01) dispensed in the pharmacies in 2007 and 2008 was analyzed, excluding antifungals, antibacterials for tuberculosis, antitumoral and topical antibiotics. According to the Law on Medicines, antibiotics are prescriptiononly medicines, prescribed by family practitioners and dispensed in the pharmacies by pharmacists, through individual prescription forms. 15 Utilization statistics were retrieved from the DRA 16 and HIF database, unpublished data are available upon request. List of medi-cines reimburesd by the HIF is published in the Republic of Srpska Official Gazzette. 17, 18 
Results
The obtained results were presented in a systematic way using different ATC levels, starting with the utilization data of the main anatomical groups (Table 1) , followed with the pharmacological subgroups of the antiinfectives for systematic use (group J) ( Fig. 1) , and subsequently presenting the results of the chemical subgroups ( Table 2 ) and active substances ( Table 3 ). Both total outpatient drugs utilization and utilization of the reimbursable drugs were increased in this period, for 10% and 26%, respectively. Total utilization of antibacterials for systemic use (J01) in 2008 decreased for 18%, while the utilization of reimbursable antibiotics increased for 2% (Table 1 ).
In total antibiotic utilization, beta-lactam penicillins were the most prescribed subgroup, followed by the subgroups of other beta-lactam antibacterials (cephalosporins), and tetracyclines. An increase in utilization of sulfonamides and trimethoprim and quinolones subgroups was observed, while the utilization of macrolides, lincosamides and streptogramins subgroup decreased. The most prescribed reimbursable antibiotic subgroup also belongs to beta-lactam penicillins. An increase in utilization was noted in subgroup of tetracyclines, while the utilization decreased in subgroups of macrolides, lincosamides and streptogramins and quinolone antibiotics ( Fig.1 It was observed that penicillins accounted for more than 50 per cent of both total and reimbursable antibiotic use. Broad-spectrum penicillins were four to five times more prescribed than the narrow-spectrum penicillins. In 2008, the total utilization broad-and narrow-spectrum penicillins decreased for 19% and 44%, respectively. The use of broad-spectrum reimbursable penicillins rose for 3 per cent, while the use of narrow-spectrum decreased for 4% ( Table 2) . Combination of amoxicillin with clavulanic acid, accounted for about 3% of the total antibiotic use, with utilization decrease. This combination was not available at the reimbursable drugs list ( Table 2 and Table 3 ).
Subgroup of tetracyclines represented about 10% of both the total and the reimbursable antibiotic utilization. Doxycycline accounted for 90% of the total tetracycline utilization, and was the only tetracycline reimbursed by the HIF ( Table 2 and Table 3 ). The utilization of sulfonamides and trimethoprim combination accounted for 10% of the total antibiotic utilization, and about 16% of reimbursed antibiotics, with an increased use noted ( Table 2 and Table  3 ). In 2008, total utilization of cephalosporins subgroup decreased, and first-generation was the most prescribed, with a noted decrease of 4%. Utilization of the second-and third-generation of cephalosporins decreased in 2008 (Table 3) . Cefalexin was the only cephalosporin antibiotic reimbursed by HIF, with 8% utilization increase in 2008 (Table 3 ). In 2008, total use of macrolides decreased for 19% and the fluoroquinolones increased for 12%, while reimbursable utilization of these both subgroups decreased ( Table 2 ).
As shown in Table 3 , amoxicilline was the most used antibiotic, and ten times more prescribed than ampicilin in 2007. We noticed that in 2008 total amoxicilline use decreased, while the reimbursed one increased for 21% and 3%, respectively. The total use of benzathine phenoxymethylpenicilline decreased compared to its reimbursable utilization increase of 18 per cent. Both total and reimbursable utilization of phenoxymethylpenicilline decreased in 2008. Total utilization of erythromycin and azithromycin declined, while the clarithromycin utilization rose for 26 per cent in 2008. Compared to 2007, utilization of reimbursed erythromycin was reduced for 7%. Ciprofloxacin was the most prescribed fluoroquinolone antibiotic, with an increased utilization. Lincomycin utilization decreased ten times.
Discussion
An increase in outpatient utilization of drugs was observed, both total utilization of all prescription-only and reimbursable drugs, similar to most developed and developing countries. 11, 12 A wide spectrum of different systemic antibiotics (J01) for outpatient use was available on our market. There was only supplying shortage in phenoxymethylpeni- cillin in 2008, due to the expiration of marketing authorization and renewal procedure run by the manufacturer in the Drug Regulatory Agency. Therefore, the utilization decrease of 3.79 DDD could be due also to the continuous education provided for the family practitioners and better adherence to the existing therapeutic guidelines. 19, 24 The variations in antibiotic use among European countries came out from the European Surveillance of Antimicrobial Consumption (ESAC) project. 3 Comparing with the participating countries, in terms of the number of DDDs, our total outpatient utilization of antibiotics of about 18 DDD was similar to Hungary, Spain and Finland 3, 25 , and comparing to our neighboring countries, is was more similar to Croatia 26,27 than to Serbia 28, 29 or Montenegro 30 .
Striking geographical variations were observed in the use of various antibiotic classes in ESAC study. Unlike penicil- lins, the most prescribed antibiotic subgroup in all countries, use tetacyclines and sulphonamides stagnated or decreased in most European countries 3 as newer antibiotics superseded them, while in our country these antibiotics were still widely used. It was found favorable penicillins still represented more a half of the total antibiotic use, but this use could be more rational as broad-spectrum penicillins were more prescribed than two narrow-spectrum penicillins available on the market. Thus, adherence to our therapeutic guidelines should be closer. Utilization of ampicilin is still notable in our country, while it was almost entirely superseded by amoxilicillin in European countries 31 . Although utilization of amoxicillin with clavulanic acid was almost cut to half in 2008, it was still nearly a half of benzatin phenoxymethylpenicillin use, and higher than phenoxymethylpenicillin utilization. Amoxicillin solely or in combination with clavulanic acid represents the more prescribed antibiotic, similar to other European countries. 3, 27, 29, 30 First-generation cephalosporins, namely cefalexin, represented more than 70% of the total cephalosporin use, like in Norway, Finland, the UK and Croatia 32, 33 Coenen et al. observed that the decrease in proportional use of first-generation cephalosporins (mainly cefalexin) was matched by an increasing use of second-and third-generation cephaloporins (mainly cefuroxime, cefaclor and cefixime) 33 , what suggests that in many countries this class of antibiotics is prescribed inappropriately. Thus, the utilization of cefuroxime, cefaclor and cefixime should be closely moni-tored in the forthcoming period. Tetracyclines utilization was more similar to Croatia and Norway than to Greece or Serbia, and doxycyclin was the most prescribed tetracycline. Combination of sulphonamides with trimethopim was widely prescribed in our country, mostly for urinary tract infections. 23,24 Utilization of 1.8 DDD was much higher than in Nordic countries 25, 32, 34 , and more similar to utilization in Croatia.
A wide use of second-generation of quinolones, namely ciprofloxacin and ofloxacin, was similar to all European countries 35 except Croatia. Norfloxacine and pipemidic acid were predominantly used for treatment of urinary tract infections, and had a stable utilization of about 0.2 DDD each.
Norfloxacin was the only reimbursable quinolone and, in terms of the number of DDDs, almost totally reimbursed by HIF. The third-generation of quinolone moxifloxacin was 2009 introduced on the reimbursable drugs list in 2009, so further monitoring of the quinolone utilization is needed, as the excessive use of quinolones is associated with development of resistance, requires more resources and exposes patients to the additional risk. Although in the majority of the European countries the intermediateacting macrolides was predominantly used, mainly clarithromycin, in some countries (Denmark, Estonia, Iceland, Norway, Sweden and the United Kingdom), however use of the short-acting macrolides was predominant 36 , like in our country. Still dominant use of erythromycin was found as rational as this could indicate cost-conscious antibiotic use, according to the therapeutic guidelines 19, 20, 22 As a shift in prescribing trends from the older to newer analogues was observed in other countries, 36 and as an increase in clarithromycin use was noted, macrolides utilization should also be closely monitored in our country. 37, 38 Availability of lincomycin in pharmacies was unexpected, as it is an antibiotic for stationary health facilities use only. Besides the violation of the Law on pharmacies 39 by the pharmacists, in order to fulfill the patient's needs, it points to the existence of certain problems in the stationary health care facilities supplying system.
Concept of the reimbursement of the first generation of antibiotics performed by HIF was found as a good one as it promotes rational antibiotics prescribing. A considerable difference between total and reimbursable antibiotic utilization in terms of the number of DDD was not expected as the HIF provides compulsory health insurance for the entire population via different categories. These utilization differences could be partially due to the existence of privately owned medical practice (mostly dental and gynecological), mostly not contracted by HIF, where one could choose to get the medical service. Prescription drugs prescribed in these facilities were purchased out-of patient's pocket in the pharmacies, especially if the drugs were of acceptable price, as the most convenient and quick access to the medicine. On the other hand, a part of these utilization differences was probably made by those patients having no health insurance due to the employer's misuse of the system in case of not paying in the contributions for compulsory health insurance. And, these are the situations were a prescribing of antibiotic is supervised by a physician. According to Cals et al. patient expectations are the strongest predictor of physician's decisions regarding antibiotic prescribing. 40 Antibiotic consumption may however also be included by self-medication. The prevalence rate of antibiotic self-medication is highest in eastern European countries, where pharmacy was the major source of selfmedication, and Matuz et al. found a positive correlation between price and non-prescription antibiotic use. 6, 41 Cultural factors and patient behavior are also known to play an important role in consumption of antibiotics as well as the past experience with antibiotic prescribing by health professionals. 8, 9, 42 Although still without a formal evidence in form of conducted survey, certain recognition with these findings was observed in our country. The increased utilization of reimbursable antibiotics in 2008, suggested that more patients were able to achieve their rights deducible form the health insurance, and that the spending out-of pocket for medicines was reduced.
In conclusion, the observed decrease in total antibiotic utilization should be continued. The list of reimbursable antibiotics comprised of the first-generation antibiotics was found rational. A utilization increase of almost all reimbursable antibiotics suggested that more patients were able to achieve their rights deducible form the health insurance, and that the spending out-of pocket for medicines was reduced. Penicillins were the most used antibiotic subgroup and amoxicilline, solely or in combination with clavulanic acid, was the most prescribed antibiotic similar to other countries. The total utilization of older antibiotics still prevail (cephalosporins, macrolides), but a shift in prescribing trends to newer analogues (penicillins, quinolones) was observed, much the same to other countries.
